Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent

    Not Recruiting
  • End date
    Nov 21, 2021
  • participants needed
  • sponsor
    Sahajanand Medical Technologies Pvt. Ltd.
Updated on 25 January 2021
Florian Irague
Primary Contact
CHRU de Montpellier (7.5 mi away) Contact
+38 other location
angina pectoris
unstable angina
stable angina


This is a prospective, multicenter, open-label, single-arm registry. The primary objective of this registry is to confirm the results of the Supraflex Cruz stent in real life all-comer patients (800 patients as in the Supraflex arm of the TALENT trial) and demonstrate that the Supraflex Cruz stent is not inferior to the BioFreedom stent in High Bleeding Risk (HBR) patients (400 patients) with respect to device oriented composite endpoint (DOCE) at 12 months. All patients will be followed up to 12 months after the index procedure.

Condition Coronary Artery Disease, Coronary heart disease
Treatment Supraflex Cruz Sirolimus-eluting Stent
Clinical Study IdentifierNCT04138238
SponsorSahajanand Medical Technologies Pvt. Ltd.
Last Modified on25 January 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note